miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

Abstract Non-small-cell lung cancer (NSCLC) is the most common malignancy worldwide. Platinum-based chemotherapy is the standard of care for these patients. Recent research showed that miR-7 methylation status is a biomarker of cisplatin resistance in lung and ovarian cancer cells, which is one of t...

Full description

Bibliographic Details
Main Authors: Carlos Rodríguez-Antolín, Laura Felguera-Selas, Olga Pernía, Olga Vera, Isabel Esteban, Itsaso Losantos García, Javier de Castro, Rocío Rosas-Alonso, Inmaculada Ibanez de Caceres
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Cell & Bioscience
Online Access:http://link.springer.com/article/10.1186/s13578-019-0326-7

Internet

http://link.springer.com/article/10.1186/s13578-019-0326-7

Similar Items